PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21392639-3	2011	Atorvastatin, omeprazole, and several other drugs have been shown in pharmacodynamic studies to competitively inhibit CYP activation of clopidogrel, reducing clopidogrel responsiveness.	Atorvastatin	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-121	
23903277-6	2013	Lipophilic statins, such as atorvastatin, are predominantly metabolized by CYP3A4 and may interfere with CYP activation of clopidogrel, contrary to what happens with hydrophilic statins, such as rosuvastin or pravastatin.	Atorvastatin	28-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-78	
11475198-4	2001	RESULT: More than 50% of the overall CYP metabolism is mediated through the isoenzyme CYP3A4, which is the main elimination route of simvastatin, lovastatin and atorvastatin.	Atorvastatin	161-173	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-40	
11122720-3	2000	Despite an excellent safety record, CYP 3A4 statins (lovastatin, simvastatin, atorvastatin) taken concomitantly with a potent CYP 3A4 inhibitor may increase the risk for adverse events (myopathy, rhabdomyolysis).	Atorvastatin	78-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-39	
11038166-1	2000	In an in vitro study, we compared the cytochrome P450 (CYP)-dependent metabolism and drug interactions of the acid and lactone forms of the 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitor atorvastatin.	Atorvastatin	197-209	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	38-53	
11038166-1	2000	In an in vitro study, we compared the cytochrome P450 (CYP)-dependent metabolism and drug interactions of the acid and lactone forms of the 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitor atorvastatin.	Atorvastatin	197-209	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	55-58	
11122720-3	2000	Despite an excellent safety record, CYP 3A4 statins (lovastatin, simvastatin, atorvastatin) taken concomitantly with a potent CYP 3A4 inhibitor may increase the risk for adverse events (myopathy, rhabdomyolysis).	Atorvastatin	78-90	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	126-129	
10575059-5	1999	The lipophilic drugs lovastatin, simvastatin, atorvastatin, cerivastatin and fluvastatin are metabolized via the cytochrome P450 (CYP450) system in the liver and the gut, making them subject to potential interactions with concomitantly administered drugs that are competing for metabolism via this system.	Atorvastatin	46-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	113-128	
10575059-5	1999	The lipophilic drugs lovastatin, simvastatin, atorvastatin, cerivastatin and fluvastatin are metabolized via the cytochrome P450 (CYP450) system in the liver and the gut, making them subject to potential interactions with concomitantly administered drugs that are competing for metabolism via this system.	Atorvastatin	46-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	130-136